evaluating post-infusion car-treg cells to identify patients resistant to cd19 car-t therapy
Published 1 year ago • 240 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
4:05
risk factors to predict post-cd19 car-t cell therapy outcomes in patients with lbcl
-
3:18
evaluating dual-targeting cd19/22 car-t cells in patients with r/r all
-
3:06
repeat infusions of cd19 car-t
-
3:01
mechanisms of antigen escape following cd19-directed car-t therapy
-
3:42
factors associated with treatment response to cd19 car t-cell therapy in b-all
-
1:28
assessment of car-t and tcr adverse events
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
5:52
chimeric antigen receptor (car) / car-t
-
9:11
chimeric antigen receptor car technique - creative biolabs (original version)
-
6:52
how to view, interpret, & export results | cellavision
-
1:55
developing the next generation of car-t cells
-
1:40
overcoming antigen escape following cd19-directed car-t therapy
-
7:35
survey on the evaluation and management of dlbcl following suboptimal response to car-t therapy
-
2:09
using lineage tracing to define responding car t-cells in patients with lbcl
-
0:59
identifying molecular markers for the prediction of icaht in patients receiving car t-cell therapy
-
1:39
the role of myeloid cells in car-t cell therapy
-
2:38
car t-cells improve response and cr rates in r/r dlbcl
-
2:01
determining which cd19-directed car-t product is best for each patient with lbcl
-
2:26
clinical data for cd19-directed car t-cell products in all
-
3:47
update on the guidelines for the diagnosis, grading & management of icaht following car-t therapy